171 related articles for article (PubMed ID: 17431776)
1. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
[No Abstract] [Full Text] [Related]
2. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
3. Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
Dusheiko G; Danta M
Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):130-1. PubMed ID: 16265150
[No Abstract] [Full Text] [Related]
4. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
5. Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation.
Wietzke P; Braun F; Ringe B; Ramadori G
Transplant Proc; 2000 Nov; 32(7):2539-42. PubMed ID: 11120284
[No Abstract] [Full Text] [Related]
6. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
[TBL] [Abstract][Full Text] [Related]
7. PEG-IFN and ribavirin re-treatment of HCV-1b cirrhosis non responder to conventional combination therapy.
Morisco F; Amoruso D; Stroffolini T; Caporaso N
Dig Liver Dis; 2008 May; 40(5):391-2. PubMed ID: 18291731
[No Abstract] [Full Text] [Related]
8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon and ribavirin for hepatitis C.
Abramowicz M
N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
[No Abstract] [Full Text] [Related]
11. A success story with chronic hepatitis C.
Weekley D; Yuen JC
J Ark Med Soc; 2005 Dec; 102(6):158-9. PubMed ID: 16381402
[No Abstract] [Full Text] [Related]
12. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
[No Abstract] [Full Text] [Related]
13. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
[No Abstract] [Full Text] [Related]
14. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
Wedemeyer H; Cornberg M; Manns MP
Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
[No Abstract] [Full Text] [Related]
15. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
16. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
Biermer M; Berg T
Gastroenterology; 2009 Jul; 137(1):390-1. PubMed ID: 19486953
[No Abstract] [Full Text] [Related]
17. Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Aguilar Reina J
Rev Esp Enferm Dig; 2009 Oct; 101(10):665-70. PubMed ID: 19899934
[No Abstract] [Full Text] [Related]
18. Summaries for patients. Sustained virologic response in hepatitis C.
Ann Intern Med; 2007 Nov; 147(10):I47. PubMed ID: 18025441
[No Abstract] [Full Text] [Related]
19. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
Lopukhova NL
Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
[No Abstract] [Full Text] [Related]
20. The treatment of viral hepatitis, present and future.
Rodés J
J Hepatobiliary Pancreat Surg; 2003; 10(2):163-7. PubMed ID: 14505150
[No Abstract] [Full Text] [Related]
[Next] [New Search]
